These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27792008)

  • 41. Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe.
    Holden SE; Currie CJ; Lennon M; Reynolds AV; Moots RJ
    Clin Exp Rheumatol; 2016; 34(4):679-84. PubMed ID: 27191345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adalimumab-associated optic neuritis.
    Chung JH; Van Stavern GP; Frohman LP; Turbin RE
    J Neurol Sci; 2006 May; 244(1-2):133-6. PubMed ID: 16527311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Challenges for biosimilars: focus on rheumatoid arthritis.
    Akram MS; Pery N; Butler L; Shafiq MI; Batool N; Rehman MFU; Grahame-Dunn LG; Yetisen AK
    Crit Rev Biotechnol; 2021 Feb; 41(1):121-153. PubMed ID: 33040628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
    Braun J; Kay J
    Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biosimilars in psoriasis: the future or not?
    Kellen R; Goldenberg G
    Cutis; 2017 Feb; 99(2):116-120. PubMed ID: 28319617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis.
    Pelechas E; Voulgari PV; Drosos AA
    Expert Opin Drug Discov; 2021 Mar; 16(3):227-234. PubMed ID: 33183071
    [No Abstract]   [Full Text] [Related]  

  • 47. Plain language summary of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis.
    Cohen SB; Lee EC
    Immunotherapy; 2022 Oct; 14(15):1183-1190. PubMed ID: 36065786
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synovial synoviolin in relation to response to TNF blockade in patients with rheumatoid arthritis and psoriatic arthritis.
    Klaasen R; Wijbrandts CA; van Kuijk AW; Pots D; Gerlag DM; Tak PP
    Ann Rheum Dis; 2012 Jul; 71(7):1260-1. PubMed ID: 22345123
    [No Abstract]   [Full Text] [Related]  

  • 49. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ABP 501 for the treatment of rheumatoid arthritis.
    Pelechas E; Voulgari PV; Drosos AA
    Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.
    Luchese MD; Lopes Dos Santos M; Garbuio A; Targino RC; Mansueli CP; Tsuruta LR; Quintilio W; Moro AM
    Immunol Res; 2018 Jun; 66(3):392-405. PubMed ID: 29855993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosimilars: impact of differences with Hatch-Waxman.
    Kowalchyk K; Crowley-Weber C
    Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GP2017: An Adalimumab Biosimilar.
    Heo YA
    BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [How I treat....psoriasis comorbidities by adalimumab (Humira) anti-TNFalpha].
    Piérard-Franchimont C; Henry F; Szepetiuk G; Piérard GE
    Rev Med Liege; 2010 Oct; 65(10):545-8. PubMed ID: 21128358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501).
    Francois F; Naimi L; Roblin X; Berger AE; Paul S
    BMC Immunol; 2021 Dec; 22(1):81. PubMed ID: 34953484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
    Metcalfe S; Moodie P; Grocott R; Wilkinson T
    N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.